Azeria Therapeutics has picked up Syncona as an investor as it looks to bring its therapy for receptor-positive luminal breast cancer into the clinic.

Azeria Therapeutics, a UK-based oncology spinout of University of Cambridge and research charity Cancer Research UK (CRUK), yesterday received £32m ($41.2m) in a series B round led by commercialisation firm Syncona.
Syncona invested approximately $38m and was joined by CRT Pioneer Fund, the investment vehicle formed by CRUK’s tech transfer arm – Cancer Research Technology – that counts Syncona as its largest investor.
Founded in 2017, Azeria is advancing drug candidates for cancer based on pioneer factors that…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?